CONBA(SH:600572)2021-10-28 16:00Financial Performance - The company's revenue for Q3 2021 was CNY 1,501,152,409.52, an increase of 11.41% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 30,910,210.30, a decrease of 151.20% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 126,157,614.80, an increase of 161.13% compared to the same period last year[5]. - The company's net profit for the first nine months of 2021 was CNY 214,693,058.22, a decrease of 60.52% year-on-year[12]. - The company reported a basic earnings per share of -0.012 yuan, a decrease of 150.11% compared to the same period last year[5]. - Net profit attributable to shareholders of the parent company for Q3 2021 was ¥214,693,058.22, down from ¥543,822,244.33 in Q3 2020, indicating a decline of approximately 60.5%[45]. - The company reported a net profit of ¥294,689,411.60 for Q3 2021, compared to ¥619,931,003.91 in Q3 2020, a decrease of around 52.4%[43]. - Earnings per share for Q3 2021 was ¥0.084, down from ¥0.212 in Q3 2020, representing a decline of approximately 60.4%[45]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 8,888,327,057.11, a decrease of 4.21% from the end of the previous year[8]. - As of September 30, 2021, the company's total assets amounted to ¥8,888,327,057.11, a decrease from ¥9,278,585,412.77 as of December 31, 2020[33]. - The company's cash and cash equivalents decreased to ¥985,504,473.85 from ¥1,575,057,825.63 year-over-year[33]. - Total current liabilities decreased to ¥2,913,651,894.04 from ¥3,252,806,194.04 year-over-year[36]. - Long-term borrowings decreased significantly to ¥200,028,588.28 from ¥502,710,229.06 year-over-year[36]. - The total liabilities decreased to ¥3,272,418,190.81 in 2021 from ¥3,929,168,800.83 in 2020, a reduction of approximately 16.7%[39]. - The total equity attributable to shareholders of the parent company increased to ¥5,259,259,941.14 in 2021 from ¥5,026,170,667.24 in 2020, reflecting a growth of about 4.6%[39]. Cash Flow - The company’s cash flow from operating activities for the first nine months was CNY 562,132,178.00, a decrease of 14.07% year-on-year[5]. - Cash inflow from operating activities for the first three quarters of 2021 was CNY 4,514,948,841.65, a decrease of 7.2% compared to CNY 4,867,908,633.46 in the same period of 2020[49]. - Net cash outflow from investing activities was CNY -120,027,272.78, compared to CNY -11,384,266.69 in the previous year, indicating a significant increase in investment expenditures[51]. - Net cash flow from financing activities was CNY -935,402,215.88, a decline from CNY -524,741,577.58 in the same period last year, reflecting higher debt repayments[51]. - Total cash and cash equivalents at the end of the period stood at CNY 899,709,745.13, down from CNY 1,460,676,056.80 at the end of the previous year[51]. - The company received CNY 4,272,919,643.39 in cash from sales of goods and services, a decrease from CNY 4,547,425,193.09 in the previous year[49]. - Cash paid to employees increased to CNY 834,679,815.94 from CNY 713,140,541.70, reflecting a rise of 17% in employee compensation[49]. - Cash outflow for other operating activities was CNY 1,561,143,375.86, down from CNY 1,925,128,367.30, indicating improved cost management[49]. - Cash inflow from investment activities totaled CNY 211,029,330.28, a decrease from CNY 416,614,624.53 in the previous year, highlighting reduced investment returns[51]. - The company reported a cash inflow of CNY 1,392,000,000.00 from borrowings, down from CNY 2,464,250,000.00 in the previous year, indicating a decrease in new financing[51]. - The company experienced a net increase in cash and cash equivalents of CNY -493,075,586.50, contrasting with a net increase of CNY 116,814,008.91 in the previous year[51]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 114,743[21]. - Zhejiang Zhongyi Medicine Health Industry Group Co., Ltd. holds 20.00% of shares, totaling 533,464,040 shares[21]. - Kang En Bei Group Co., Ltd. holds 8.11% of shares, totaling 216,284,371 shares[21]. Asset Transfers and Strategy - The company has completed the transfer of a 30% stake in Lanxin Microfinance Company for a total of 53.37 million RMB[24]. - The company is in the process of transferring a 42% stake in Jiangxi Zhenzhiming Pharmaceutical Co., Ltd., with an estimated value of 1,450,680,000 RMB[25]. - The estimated total equity value of Jiangxi Zhenzhiming is 4 billion RMB, with a minimum transfer price set at 1.68 billion RMB[25]. - The company is also transferring 100% of Guizhou Bait Company, with an estimated value of 203,643,612.64 RMB[26]. - The transfer of Guizhou Bait Company is set with a minimum transfer price of 203,643,613 RMB[26]. - The company aims to focus on the core business of traditional Chinese medicine health industry through these asset transfers[24]. Research and Development - The company has initiated a new product development strategy, focusing on enhancing its pharmaceutical offerings[29]. - Research and development expenses for the first three quarters of 2021 amounted to ¥135,739,532.07, compared to ¥127,761,353.13 in the same period of 2020, showing an increase of about 6.2%[43]. Other Financial Metrics - The company recognized a fair value change loss of CNY 28,439,330.00 related to its holdings in Genor Biopharma, affecting net profit[13]. - Excluding the impacts from Genor Biopharma and Guizhou Bait, the company's net profit for the first nine months would have increased by approximately 43.76% year-on-year[15]. - The company is currently in the creditor declaration period for the share cancellation, which lasts from September 30, 2021, to November 15, 2021[29]. - Total operating revenue for the first three quarters of 2021 reached ¥4,620,666,505.05, an increase from ¥4,542,445,465.87 in the same period of 2020, representing a growth of approximately 1.7%[39]. - Total operating costs decreased to ¥4,039,994,729.28 in 2021 from ¥4,067,536,050.68 in 2020, reflecting a reduction of about 0.7%[39]. - The company reported a decrease in financial expenses to ¥46,933,858.31 in Q3 2021 from ¥85,910,024.88 in Q3 2020, a reduction of about 45.3%[43]. - Deferred income tax liabilities decreased to ¥25,160,263.02 in 2021 from ¥74,311,929.97 in 2020, indicating a decline of approximately 66.1%[39].